1 |
Akkiz H, Bayram S, Bekar A, et al (2009). G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 33, 261-4.
DOI
ScienceOn
|
2 |
Antoniou AC, Beesley J, McGuffog L, et al (2010). Common breast cancer susceptibility alleles and the risk of breast cancer of BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res, 70, 9742-54.
DOI
ScienceOn
|
3 |
Ataseven H, Bahcecioglu IH, Kuzu N, et al (2006). The levels of ghrelin, leptin, TNF-alpha, and IL-6 in lever cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm, 2006, 78380.
|
4 |
Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). A functional polymorphism in the epidermal growth factor gene is associated with the risk of hepatocellular carcinoma. Gastroenterology, 141, 141-9.
DOI
ScienceOn
|
5 |
Burchard J, Zhang C, Liu AM, et al (2010). MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol, 6, 402.
|
6 |
Bao Y, Yan Y, Xu C, et al (2013). MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett, 337, 226-36.
DOI
ScienceOn
|
7 |
Beasley RP, Lin CC, Hwang LY, et al (1981). Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 Men in Taiwan. Lancet, 318, 1129-33.
DOI
ScienceOn
|
8 |
Bihrer V, Waidmann O, Friedrich-Rust M, et al (2011). Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One, 6, e26971.
DOI
|
9 |
Chan HL, Hui AY, Wong ML, et al (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-8.
DOI
ScienceOn
|
10 |
Chan HL, Tse CH, Mo F, et al (2008). High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol, 26, 177-82.
DOI
ScienceOn
|
11 |
Chen K, Wei Y, Yang H, Li B (2011). Epidermal growth factor +61 G/A polymorphism and the hepatocellular carcinoma in a Chinese population. Genet Test Mol Biomarkers, 15, 251-5.
DOI
ScienceOn
|
12 |
Chen X, Zhang L, Chang Y, et al (2011). Association of TNFalpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han population. Int J Biol Markers, 26, 181-7.
DOI
ScienceOn
|
13 |
Cho LY, Yang JJ, Ko KP, et al (2011). Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer, 128, 176-84.
DOI
ScienceOn
|
14 |
Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF (2012). Viral load, genotypes, and mutants in Hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci, 57, 232-8.
DOI
ScienceOn
|
15 |
Cougot D, Neuveut C, Buendia MA (2005). HBV induced carcinogenesis. J Clin Virol, 34, S75-8.
|
16 |
Gao ZY, Li T, Wang J, et al (2007). Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol, 42,761-8.
DOI
|
17 |
Du Cl, Wang JD (1998). Increased morbidity odds ratio of primary liver cancer and cirrhosis of the liver among vinyl chloride monomer workers. Occup Environ Med, 55, 528-32.
DOI
|
18 |
Ezzikouri S, El Feydi AE, Chafik A, et al (2007). The Pro variant of the p53 codon72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res, 37, 748-54.
DOI
ScienceOn
|
19 |
Gao C, Zhao HC, Li JT, Yao SK (2010). Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol, 16, 4467-75.
DOI
|
20 |
Giannitrapani L, Soresi M, Giacalone A, et al (2011). IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS, 15, 183-6.
DOI
ScienceOn
|
21 |
Gui JH, Tian YP, Wen XY, et al (2011). Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci, 120, 183-93.
DOI
ScienceOn
|
22 |
Hassan MM, Curley SA, Li D, et al (2010). Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer, 116, 1938-46.
DOI
ScienceOn
|
23 |
Hung CH, Lee CM, Wang JH, et al (2011). Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer, 128, 2344-52.
DOI
ScienceOn
|
24 |
Hung CH, Lu SN, Wang JH, et al (2011). Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther, 16, 959-68.
DOI
|
25 |
International Agency for Research on Cancer (2009). Cancer Incidence and Mortality Worldwide in 2008. Lyon: IARC.
|
26 |
Hung CH, Wang JH, Hu TH, et al (2010). Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol, 16, 2265-71.
DOI
|
27 |
Imai Y, Tamura S, Tanaka H, et al (2010). Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat, 17, 185-91.
DOI
ScienceOn
|
28 |
International Agency for Research on Cancer (2008). Word Cancer Report 2008. Lyon: IARC.
|
29 |
Ito K, Tanaka Y, Orito E, et al (2006). T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis, 42, 1-7.
DOI
|
30 |
Jardi R, Rodriguez F, Buti M, et al (2001). Role of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutation on viral replicative interference. Hepatology, 34, 404-10.
DOI
ScienceOn
|
31 |
Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
32 |
Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 284, 31-53.
DOI
ScienceOn
|
33 |
Koberle V, Kronenberger B, Pleli T, et al (2013). Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, Epub ahead of print.
|
34 |
Lemke LB, Rogers AB, Nambiar PR, Fox JG (2008). Obesity and non-insulin-dependent diabetes mellitus in Swiss-Webster mice associated with late-onset hepatocellular carcinoma. J Endocrinol, 199, 21-32.
DOI
ScienceOn
|
35 |
Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M (1987). Cigarette smoking, alcohol and cancer mortality: a cohort study of male Japanese physicians. Jpn J Cancer Res, 78, 1323-8.
|
36 |
Kumar V, Kato N, Urabe Y, et al (2011). Genome-wide association study identifies a susceptibility locus for HCVinduced hepatocellular carcinoma. Nat Genet, 43, 455-8.
DOI
ScienceOn
|
37 |
Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
|
38 |
Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.
DOI
ScienceOn
|
39 |
Li P, Du Q, Cao Z, et al (2012). Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferonregulatory factor-1 (IRF-1). Cancer Lett, 314, 213-22.
DOI
ScienceOn
|
40 |
Li YJ, Xie Q, Lu FM, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8.
DOI
ScienceOn
|
41 |
Liaw J, Marshall G, Yuan Y, et al (2008). Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev, 17, 1982-7.
DOI
ScienceOn
|
42 |
Liu F, Li B, Wei Y, et al (2011). XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a metaanalysis. Liver Int, 31, 802-9.
DOI
ScienceOn
|
43 |
Lin SM, Yu ML, Lee CM, et al (2007). Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocelluar carcinoma. J Hepatol, 46, 45-52.
DOI
ScienceOn
|
44 |
Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carries. J Infect Dis, 193, 1258-65.
DOI
ScienceOn
|
45 |
Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis, 194, 594-9.
DOI
ScienceOn
|
46 |
Liu H, Ye L, Wang QW, Yan QX, Yu JM (2009). Effect of conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway. Chin Med J, 122, 460-5.
|
47 |
Long XD, Ma Y, Huang HD, et al (2008). Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China. Mol Carcinog, 47, 295-300.
DOI
ScienceOn
|
48 |
Long XD, Ma Y, Wei YP, Deng ZL (2006). The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, 36, 48-55.
DOI
ScienceOn
|
49 |
Loomba R, Yang HI, Su J, et al (2013). Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol, 177, 333-42.
DOI
ScienceOn
|
50 |
Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer, 7, 162.
DOI
|
51 |
Lv L, Wang P, Zhou X, Sun B (2013). Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol, 34, 1451-9.
DOI
ScienceOn
|
52 |
Ma L, Teruya-Feldstein J, Weinberg RA (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682-8.
DOI
ScienceOn
|
53 |
Mendy ME, Welzel T, Lesi OA, et al (2010). Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat, 17, 115-22.
DOI
ScienceOn
|
54 |
Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58.
DOI
ScienceOn
|
55 |
Ministry of health of the people's republic of China (2010). China health statistical yearbook in 2010. The first edition. Beijing, Peking union medical college press.
|
56 |
Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV (1998). Immune pathogenesis of hepatocellular carcinoma. J Exp Med, 188, 341-50.
DOI
|
57 |
Miyake, Y, Kobashi H, Yamamoto K (2009). Meta-analysis: the effect of interferon on development of hepatocellular carcinoma with patients with chronic hepatitis B virus infection. J Gastroenterol, 44, 470-5.
DOI
|
58 |
Mizuguchi Y, Mishima T, Yokomuro S, et al (2011). Sequencing and bioinformatics-based analyses of the mircoRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One, 6, e15304.
DOI
ScienceOn
|
59 |
Oh JK, Shin HR, Lim MK, et al (2012). Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and co-infected subjects in HBV endemic area:a community-based cohort study. BMC Cancer, 12, 452.
DOI
|
60 |
Mun HS, Lee SA, Kim H, et al (2011). Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocelluar carcinoma in patients with chronic genotype C infections. J Virol, 85, 123-32.
DOI
ScienceOn
|
61 |
Parkin DM (2006). The global health burden of infectionassociated cancers in the year 2002. Int J Cancer, 8, 3030-44.
|
62 |
Polesel J, Zucchetto A, Montella M, et al (2009). The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol, 20, 353-7.
|
63 |
Porkka KP. Pfeiffer MJ, Waltering KK, et al (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-5.
DOI
ScienceOn
|
64 |
Qu LS, Jin F, Huang XW, Ge YS (2010). Interferon- therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol, 102, 796-801.
DOI
ScienceOn
|
65 |
Saito I, Miyamura T, Ohbayashi A, et al (1990). Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A, 87, 6547-9.
DOI
|
66 |
Saunders D, Seidel D, Alison M, Lyratzopoulos G (2010). Systematic review: the association between obesity and hepatocellular carcinoma- epidemiological evidence. Aliment Pharmacol Ther, 31, 1051-63.
|
67 |
Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42.
|
68 |
Shafritz DA, Shouval D, Sherman HI, Hadziuannis SJ, Kew MC (1981). Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocelluar carcinoma. Studies in percutaneous liver biopsies and postmortem tissue specimens. N Engl J Med, 305, 1067-73.
DOI
ScienceOn
|
69 |
Soga K, Shibasaki K, Aoyagi Y (2005). Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology, 52, 1154-8.
|
70 |
Sopipong W, Tangkivanich P, Payungporn S, Posuwan N, Poovorawan Y. The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai Patients. Asian Pac J Cancer Prev, 14, 2865-9.
|
71 |
Sumbul AT, Akkiz H, Bayram S, et al (2012). p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 1639-47.
DOI
|
72 |
Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, 299, 53-60.
|
73 |
Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613 and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458.
DOI
|
74 |
Thompson KJ, Swan RZ, Walling TL, et al (2013). Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular caricinoma in vivo. Surg Endosc, 27, 2782-91.
DOI
ScienceOn
|
75 |
Wei W, Liu F, Liu L, et al (2011). Distinct mutations in MLH1 and MSH2 genes in hereditary non-polyposis colorectal cancer (HNPCC) families from China. BMP Rep, 44, 317-22.
DOI
ScienceOn
|
76 |
Tomimaru Y, Eguchi H, Nagano H, et al (2010). MicroRNA-21 induces resistance to the anti-tumor effect of interferon-/5- fluorouracil in hepatocellular carcinoma cells. Br J Cancer, 103, 1617-26.
DOI
ScienceOn
|
77 |
Wang C, Wang X, Gong G, et al (2012). Increased risk of hepatocellular carcinoma in patients with diabete mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer, 130, 1639-48.
DOI
ScienceOn
|
78 |
Wang Z, Gao Q, Shi JY, et al (2013). Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. PLoS One, 25, e62571.
|
79 |
Wu CF, Yu MW, Lin CL, et al (2008). Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis, 29, 106-12.
DOI
|
80 |
Wu D, Jiang H, Gu Q, Zhang D, Li Z (2013). Association between XRCC1 Arg399Gln polymorphism and hepatitis virus related hepatocellular carcinoma risk in Asian population. Tumour Biol, Epub ahead of print.
|
81 |
Yang JQ, Pan GD, Chu GP, et al (2008). Interferon-alpha restrains growth and invasive potential of hepatocellular induced by hepatitis B virus X protein. World J Gastroenterol, 14, 5564-9.
DOI
|
82 |
Yu ML, Lin SM, Chuang WL, et al (2006). A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther, 11, 985-94.
|
83 |
Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8.
DOI
ScienceOn
|
84 |
Yang YF, Zhao W, Zhong YD, et al (2009). Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat, 16, 265-71.
DOI
ScienceOn
|
85 |
Yin H, Xie F, Zhang J, et al (2011). Combination of interferon- and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett, 306, 34-42.
DOI
ScienceOn
|
86 |
Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6.
DOI
ScienceOn
|
87 |
Zhang CH, Xu GL. Jia WD, et al (2009). Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a metaanalysis of randomized controlled trials. Int J Cancer, 124, 2982-8.
DOI
ScienceOn
|
88 |
Zhang CH, Xu GL, Jia WD, et al (2011). Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a metaanalysis of randomized controlled trials. Int J Cancer, 129, 1254-64.
DOI
ScienceOn
|
89 |
Zheng JX, Zeng Z, Zheng YY, et al (2011). Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype patients. J Viral Hepat, 18, e423-31.
DOI
ScienceOn
|
90 |
Zhang J, Yang Y, Yang T, et al (2010). MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppress cell proliferation and tumourigenicity. Br J Cancer, 103, 1215-20.
DOI
ScienceOn
|
91 |
Zhuang PY, Zhang JB, Zhang W, et al (2010). Long-term interferon- treatment suppresses tumor growth but promotes metastasis capacity in hepatocelluar carcinoma. J Cancer Res Clin Oncol, 136, 1891-900.
DOI
|
92 |
Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9.
DOI
ScienceOn
|
93 |
Zhao BH, Liu F, Liu S, Niu JJ, et al (2011). A case-control study of the association between human exposure to selected chlorinated pesticides and primary hepatocellular carcinoma. Epidemiology, 22, p S 145.
|
94 |
Zhou J, Yu L, Gao X, et al (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29, 4781-8.
DOI
ScienceOn
|
95 |
Zhang HX, Zhai Y, Hu ZB, et al (2010). Genomoe-wide association study identifies 1p36.22 as new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carries. Nat Genet, 42, 755-8.
DOI
ScienceOn
|
96 |
Howlader N, Noone AM, Krapcho M, et al (2011). EER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site.
|
97 |
Adami HQ, Hsing AW, McLaughlin JK, et al (1992). Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer, 51, 898-902.
DOI
|
98 |
Koh WP, Wang R, Jin A, Yu MC, Yuan JM (2013). Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer, 108, 1182-8.
DOI
ScienceOn
|
99 |
Li Q, Li WW, Fan WB, et al (2012). Type 2 diabetes and hepatocellular carcinoma: A case-control study in patients with chronic hepatitis B. Int J Cancer, 131, 1997-202.
|